Meta-analysis on efficacy of Nosenazone sodium in treatment of patients with spinal muscular atrophy

doi:10.3760/cma.j.issn.1007-1245.2024.17.016

Abstract

Abstract:

Objective　To verify the effectiveness of Nosenazone sodium in the treatment of patients with spinal muscular atrophy (SMA) by meta-analysis. Methods　The study objects were the patients with SMA treated by Nosenazone sodium. The databases, such as VIP Database, China National Knowledge Infrastructure, Wanfang Database, PubMed, et., were systematically searched from January 2016 to June 2023. RevMan5.7 was used to do the meta-analysis. The effectiveness of Nosenazone sodium for the domestic and foreign cases of SMA was systematically analyzed. Results　A total of 232 patients with SMA were included in 11 literatures. The risk difference for improvement in SMA patients treated by Nosenazone sodium was 0.67 (95%CI 0.39-0.96). Conclusion　Nosenazone sodium for patients with SMA is obviously effective.

Key words:

Spinal muscular atrophy, Nosenazone sodium, Meta-analysis, Disease , burden

摘要：

目的　采用meta分析验证诺西那生钠治疗脊髓性肌萎缩症（spinal muscular atrophy，SMA）的有效性。方法　以诺西那生纳治疗的SMA患者为研究对象，系统检索2016年1月至2023年6月期间的维普数据库、中国知网、万方数据库、PubMed等数据库，采用RevMan5.7统计软件进行meta分析，合并国内外病例，系统分析诺西那生钠治疗SMA的有效性。结果　纳入11篇文献，共232例SMA患者。SMA患者使用诺西那生钠治疗后健康改善的危险度差为0.67，95%CI 0.39～0.96。结论　诺西那生钠治疗SMA效果显著。

关键词:

脊髓性肌萎缩症, 诺西那生钠, meta分析, 疾病负担

Zhou Xingyu, Zeng Jing.

Meta-analysis on efficacy of Nosenazone sodium in treatment of patients with spinal muscular atrophy [J]. International Medicine and Health Guidance News, 2024, 30(17): 2900-2904.

周星雨曾靓.

诺西那生钠治疗脊髓性肌萎缩症效果的meta分析 [J]. 国际医药卫生导报, 2024, 30(17): 2900-2904.

References

[1] 吕鹤,袁云. 肌萎缩诊断和鉴别诊断[J]. 中国实用内科杂志,2009,29(2):97-100.
[2] Pearn J. Classification of spinal muscular atrophies[J]. Lancet, 1980,1(8174):919-922. DOI: 10.1016/s0140-6736(80)90847-8.
[3] 美儿SMA关爱中心.«中国SMA患者生活质量研究»[E]. http://www.meier.org. cn/down load. 2020-08-07.
[4] 章毅,陈朔晖,罗飞翔,等. 脊髓性肌萎缩症患儿鞘内注射诺西那生钠注射液的护理[J]. 中华护理杂志,2020,55(9):1409-1412. DOI:10.3761/j.issn.0254-1769.2020.09.025.
[5] 阳娜,章毅,潘丽丽,等. 脊髓性肌萎缩Ⅰ型患儿鞘内注射诺西那生钠注射液1例的护理[J]. 护理与康复,2021,20(9):47-49. DOI:10.3969/j.issn.1671-9875.2021.09.014.
[6] 邓海英,胡君,黄丽琴,等. 脊髓性肌萎缩症患儿行多学科协作的护理[J]. 中华急危重症护理杂志,2022,3(1):41-43. DOI:10.3761/j.issn.2096-7446.2022.01.006.
[7] 罗智强,路新国,刘丽琴,等. 诺西那生钠治疗症状前5q脊髓性肌萎缩症1例疗效分析[J]. 临床儿科杂志,2022,40(3):208-211. DOI:10.12372/jcp.2022.21e1539.
[8] 毛姗姗,冯艺杰,徐璐,等. 诺西那生钠修正治疗儿童脊髓性肌萎缩症随访分析[J]. 中华儿科杂志,2022,60(7):688-693. DOI:10.3760/cma.j.cn112140-20211223-01075.
[9] 马荣慧,李艳萍,王琛雅,等.诺西那生钠药物联合康复训练护理在脊髓性肌萎缩患者运动功能中的效果观察[J].中文科技期刊数据库(全文版)医药卫生,2022(9):0256-0259.
[10] 齐红阳,李文欢,王华. Ⅱ型脊髓肌肉萎缩症患儿基因治疗的护理[J]. 中国实用护理杂志,2022,38(17):1344-1347. DOI:10.3760/cma.j.cn211501-20210512-01367.
[11] 陈峥,Yoram Nevo,Tanya Moss. 诺西那生治疗脊髓性肌萎缩[J]. 中国临床研究,2019,32(6):721-725. DOI:10.13429/j.cnki.cjcr.2019.06.001.
[12] Acsadi G, Crawford TO, Müller-Felber W, et al. Safety and efficacy of nusinersen in spinal muscular atrophy: the EMBRACE study[J]. Muscle Nerve, 2021,63(5):668-677. DOI: 10.1002/mus.27187.
[13] Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy[J]. N Engl J Med, 2017,377(18):1723-1732. DOI: 10.1056/NEJMoa1702752.
[14] Mercuri E, Darras BT, Chiriboga CA, et al. Nusinersen versus Sham control in later-onset spinal muscular atrophy[J]. N Engl J Med, 2018,378(7):625-635. DOI: 10.1056/NEJMoa1710504.
[15] Kolb SJ, Kissel JT. Spinal muscular atrophy: a timely review[J]. Arch Neurol, 2011,68(8):979-984. DOI: 10.1001/archneurol.2011.74.
[16] 徐盈,黎昱,宋婷婷,等. 6616例脊髓性肌萎缩症携带者筛查及高风险胎儿产前诊断分析[J]. 实用妇产科杂志,2020,36(1):42-47.
[17] 谭建强,张旭,王远流,等. 广西柳州地区4931例孕妇脊髓性肌萎缩症突变携带者的筛查及产前诊断[J]. 中华医学遗传学杂志,2018,35(4):467-470. DOI:10.3760/cma.j.issn.1003-9406.2018.04.001.
[18] 李吉明,邢清和. 脊髓性肌萎缩症携带者产前筛查的几种实用技术[J/CD]. 中国产前诊断杂志(电子版),2021,13(2):59-63. DOI:10.13470/j.cnki.cjpd.2021.02.013.
[19] Prior TW. Spinal muscular atrophy diagnostics[J]. J Child Neurol, 2007,22(8):952-956. DOI: 10.1177/0883073807305668.
[20] Chiriboga CA. Pharmacotherapy for spinal muscular atrophy in babies and children: a review of approved and experimental therapies[J]. Paediatr Drugs, 2022,24(6):585-602. DOI: 10.1007/s40272-022-00529-8.
[21] 张淑霞,夏蕾,周燕,等. 婴儿脊髓性进行性肌萎缩一家3例报告[J]. 河北医药,2002,24(1):76. DOI:10.3969/j.issn.1002-7386.2002.01.060.
[22] 冯春,郑芳,彭剑虹,等.脊髓性肌萎缩症产前诊断病例分析并遗传咨询指导[J].中国优生与遗传杂志,2017,25(10):94-96+119.DOI:10.13404/j.cnki.cjbhh.2017.10.040.
[23] 孟英韬,宋力,陈红苓,等. MLPA技术应用于SMA基因诊断及相邻基因相关性研究[C]. //中华医学会第十七次全国儿科学术大会论文集. 2012:1289-1290.
[24] 谭建强,罗世强,唐宁,等.脊髓性肌萎缩症患儿17例临床特点分析及基因诊断[J].中国优生与遗传杂志,2018,26(03):23-24,18,2.DOI:10.13404/j.cnki.cjbhh.2018.03.008.
[25] Nurputra DK, Lai PS, Harahap NI, et al. Spinal muscular atrophy: from gene discovery to clinical trials[J]. Ann Hum Genet, 2013,77(5):435-463. DOI: 10.1111/ahg.12031.
[26] 徐盈,张建芳,郭芬芬,等. 三种单基因遗传病的产前分子诊断[J/CD]. 中国产前诊断杂志(电子版),2014(4):37-42. DOI:10.13470/j.cnki.cjpd.2014.04.011.
[27] 石力,韩艾.醒脑开窍针刺法治疗进行性脊髓性肌萎缩1例[J].上海针灸杂志,2010,29(05):314.DOI:10.13460/j.issn.1005-0957.2010.05.010.
[28] 王旭,邹丽萍,周文敏,等. 鼠神经生长因子治疗儿童脊髓性肌萎缩症的临床研究[J]. 军医进修学院学报,2010,31(12):1153-1155.
[29] 杜玲,杨华强,罗国君.脐血干细胞移植治疗中间型脊髓性肌萎缩症1例并文献复习[J].现代生物医学进展,2011,11(09):1764-1766.DOI:10.13241/j.cnki.pmb.2011. 09.028.
[30] 刘洋,张华.脊髓性肌萎缩症Ⅱ型患者1例并文献复习[J].中风与神经疾病杂志,2020,37(01):70-71.DOI:10.19845/j.cnki.zfysjjbzz.2020.01.018.
[31] 张洁晶,吕芳芳,温顺航,等. 儿童脊髓性肌萎缩合并肺部感染36例诊治分析[J]. 中国实用儿科杂志,2019,34(8):666-669,688. DOI:10.19538/j.ek2019080612.
[32] 王文俏,毛姗姗,马鸣. 脊髓性肌萎缩症患儿营养管理研究进展[J]. 临床儿科杂志,2022,40(3):235-240. DOI:10.12372/jcp.2022.21e1244.
[33] 郭文卉,常丽,曹玲. 脊髓性肌萎缩相关呼吸系统疾病诊疗方案[J]. 中国医刊,2016,51(11):10-14. DOI:10.3969/j.issn.1008-1070.2016.11.004.
[34] Abbas KS, Eltaras MM, El-Shahat NA, et al. The safety and efficacy of Nusinersen in the treatment of spinal muscular atrophy: a systematic review and meta-analysis of randomized controlled trials[J]. Medicina (Kaunas), 2022,58(2):213. DOI: 10.3390/medicina58020213.